<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196284</url>
  </required_header>
  <id_info>
    <org_study_id>NN7415-4310</org_study_id>
    <secondary_id>U1111-1179-2925</secondary_id>
    <secondary_id>2016-000510-30</secondary_id>
    <secondary_id>JapicCTI-173681</secondary_id>
    <nct_id>NCT03196284</nct_id>
  </id_info>
  <brief_title>A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors</brief_title>
  <acronym>explorerâ„¢4</acronym>
  <official_title>A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Africa, Asia, Europe and North America. The aim of the trial is to
      assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once
      daily in preventing bleeding episodes in haemophilia A and B patients with inhibitors.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 10, 2017</start_date>
  <completion_date type="Anticipated">November 14, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 29, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of bleeding episodes</measure>
    <time_frame>Week 0 - 24</time_frame>
    <description>Count of episodes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of bleeding episodes</measure>
    <time_frame>Week 0 - 76</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of spontaneous bleeding episodes</measure>
    <time_frame>Week 0 - 24</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of spontaneous bleeding episodes</measure>
    <time_frame>Week 0 - 76</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Week 0 - 24</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of TEAEs</measure>
    <time_frame>Week 0 - 76</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of TEAEs</measure>
    <time_frame>0 - 24 hours after eptacog alfa administration</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of anti-concizumab antibodies</measure>
    <time_frame>Week 0 - 24</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of anti-concizumab antibodies</measure>
    <time_frame>Week 0 - 76</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fibrinogen</measure>
    <time_frame>Week 0, week 24</time_frame>
    <description>Measured in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fibrinogen</measure>
    <time_frame>Week 0, week 76</time_frame>
    <description>Measured in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in D-dimer</measure>
    <time_frame>Week 0, week 24</time_frame>
    <description>Measured in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in D-dimer</measure>
    <time_frame>Week 0, week 76</time_frame>
    <description>Measured in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in prothrombin fragment</measure>
    <time_frame>Week 0, week 24</time_frame>
    <description>Measured in pmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in prothrombin fragment</measure>
    <time_frame>Week 0, week 76</time_frame>
    <description>Measured in pmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in prothrombin time (PT)</measure>
    <time_frame>Week 0, week 24</time_frame>
    <description>Measured in seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in prothrombin time (PT)</measure>
    <time_frame>Week 0, week 76</time_frame>
    <description>Measured in seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in activated partial thromboplastin time (APTT)</measure>
    <time_frame>Week 0, week 24</time_frame>
    <description>Measured in seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in activated partial thromboplastin time (APTT)</measure>
    <time_frame>Week 0, week 76</time_frame>
    <description>Measured in seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anti-thrombin (AT)</measure>
    <time_frame>Week 0, week 24</time_frame>
    <description>Measured in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anti-thrombin (AT)</measure>
    <time_frame>Week 0, week 76</time_frame>
    <description>Measured in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of concizumab</measure>
    <time_frame>Prior to the last dose administration at 24 weeks</time_frame>
    <description>Measured in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of concizumab</measure>
    <time_frame>Prior to the last dose administration at 76 weeks</time_frame>
    <description>Measured in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free TFPI concentration value</measure>
    <time_frame>Prior to the last dose administration at 24 weeks</time_frame>
    <description>Measured in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free TFPI concentration value</measure>
    <time_frame>Prior to the last dose administration at 76 weeks</time_frame>
    <description>Measured in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak thrombin generation</measure>
    <time_frame>Prior to the last dose administration at 24 weeks</time_frame>
    <description>Measured in nM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak thrombin generation</measure>
    <time_frame>Prior to the last dose administration at 76 weeks</time_frame>
    <description>Measured in nM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endogenous thrombin potential</measure>
    <time_frame>Prior to the last dose administration at 24 weeks</time_frame>
    <description>Measured in nM x min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endogenous thrombin potential</measure>
    <time_frame>Prior to the last dose administration at 76 weeks</time_frame>
    <description>Measured in nM x min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation velocity index</measure>
    <time_frame>Prior to the last dose administration at 24 weeks</time_frame>
    <description>Measured in nM/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation velocity index</measure>
    <time_frame>Prior to the last dose administration at 76 weeks</time_frame>
    <description>Measured in nM/min</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Congenital Bleeding Disorder</condition>
  <condition>Haemophilia A With Inhibitors</condition>
  <condition>Haemophilia B With Inhibitors</condition>
  <arm_group>
    <arm_group_label>Concizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concizumab administered in both the main phase and extension phase, with eptacog alfa administered on-demand during bleeding episodes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eptacog alfa and concizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eptacog alfa administered on-demand during bleeding episodes as the only intervention during the main phase. Concizumab given in the extension phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concizumab</intervention_name>
    <description>A loading dose of 0.5 mg/kg will be given as the first dose, followed by 0.15 mg/kg (with potential stepwise dose escalation to 0.25 mg/kg) administered daily s.c. (subcutaneously, under the skin). Treatment duration is 24 weeks in the main trial, and up to 52 weeks in the extension phase</description>
    <arm_group_label>Concizumab</arm_group_label>
    <arm_group_label>Eptacog alfa and concizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eptacog alfa</intervention_name>
    <description>A single dose of 90 Î¼g/kg eptacog alfa one week after dosing with concizumab. On-demand treatment during bleeding episodes in both treatment arms</description>
    <arm_group_label>Concizumab</arm_group_label>
    <arm_group_label>Eptacog alfa and concizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained before any trial related activities. Trial related
             activities are any procedures that are carried out as part of the trial, including
             activities to determine the suitability for the trial

          -  Male haemophilia A or B patients with inhibitors aged 18 years or older at the time of
             signing informed consent

          -  Patients currently in need of treatment with bypassing agents

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to trial product(s) or related products

          -  Known inherited or acquired bleeding disorder other than haemophilia

          -  Ongoing or planned immune tolerance induction therapy or prophylaxis with FVIII or FIX
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ã…rhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>GR-11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kashihara-shi, Nara</city>
        <zip>634 8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nagoya-shi, Aichi</city>
        <zip>466 8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Suginami-ku, Tokyo</city>
        <zip>167 0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Georgetown, Penang</city>
        <zip>10450</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kota Kinabalu</city>
        <zip>88586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Solna</city>
        <zip>171 64</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lviv</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Denmark</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Malaysia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to disclosure commitment on novonordisk-trials.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

